Therapy Directory

Pomalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention. Browse Pomalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

204

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Multiple Myeloma
Interventions: Selinexor, Dexamethasone; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL
Interventions: Nivolumab, Pomalidomide; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Relapsed and/or Refractory Multiple Myeloma
Interventions: Ixazomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Santa Rosa, California • Boca Raton, Florida + 7 more

Conditions: Multiple Myeloma
Interventions: Melphalan flufenamide (Melflufen), Dexamethasone; Drug
Lead sponsor: Oncopeptides AB; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 9
States / cities: Whittier, California • Gainesville, Florida • Chicago, Illinois + 6 more

Conditions: Multiple Myeloma, Renal Impairment
Interventions: 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more

Conditions: Kaposi Sarcoma, Sarcoma, Kaposi
Interventions: Pomalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Hackensack, New Jersey + 5 more

Conditions: Multiple Myeloma
Interventions: Not listed
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: No City Provided, New Jersey

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Pomalidomide; Biological · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Wichita, Kansas • Rochester, Minnesota • Saint Louis Park, Minnesota + 2 more

Conditions: Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Primary Central Nervous System Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 20 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Encinitas, California • Fountain Valley, California • Monterey, California + 3 more

About this Pomalidomide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pomalidomide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pomalidomide clinical trials

Filter and sort this therapy

Live official records

Selinexor Treatment of Refractory Myeloma

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Combination Study for High Risk Multiple Myeloma Patients

About this Pomalidomide clinical trials directory page